Original article<Br>Should perimembranous ventricular septal defects still be treated percutaneously?

Małgorzata Pawelec-Wojtalik; Waldemar Bobkowski; Bartłomiej Mroziński; Rafał Surmacz; Wojciech Mrówczyński; Andrzej Wodziński; Alicja Bartkowska-Śniatkowska; Rafał Bartkowski; Arkadiusz Biniaś

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2008
vol. 4

Send email

Copy url:

abstract:

Original article
Should perimembranous ventricular septal defects still be treated percutaneously?

Małgorzata Pawelec-Wojtalik

,

Waldemar Bobkowski

,

Bartłomiej Mroziński

,

Rafał Surmacz

,

Wojciech Mrówczyński

,

Andrzej Wodziński

,

Alicja Bartkowska-Śniatkowska

,

Rafał Bartkowski

,

Arkadiusz Biniaś

Post Kardiol Interw 2008; 4, 1 (11): 1–9

Online publish date: 2008/04/10

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Pawelec-Wojtalik M, Bobkowski W, Mroziński B, et al. Original articleShould perimembranous ventricular septal defects still be treated percutaneously?. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2008;4(1):1-9.

APA

Pawelec-Wojtalik, M., Bobkowski, W., Mroziński, B., Surmacz, R., Mrówczyński, W.,  & Wodziński, A. et al. (2008). Original articleShould perimembranous ventricular septal defects still be treated percutaneously?. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 4(1), 1-9.

Chicago

Pawelec-Wojtalik, Małgorzata, Waldemar Bobkowski, Bartłomiej Mroziński, Rafał Surmacz, Wojciech Mrówczyński, Andrzej Wodziński,  and Alicja Bartkowska-Śniatkowska et al. 2008. "Original articleShould perimembranous ventricular septal defects still be treated percutaneously?". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 4 (1): 1-9.

Harvard

Pawelec-Wojtalik, M., Bobkowski, W., Mroziński, B., Surmacz, R., Mrówczyński, W., Wodziński, A., Bartkowska-Śniatkowska, A., Bartkowski, R.,  and Biniaś, A. (2008). Original articleShould perimembranous ventricular septal defects still be treated percutaneously?. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 4(1), pp.1-9.

MLA

Pawelec-Wojtalik, Małgorzata et al. "Original articleShould perimembranous ventricular septal defects still be treated percutaneously?." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 4, no. 1, 2008, pp. 1-9.

Vancouver

Pawelec-Wojtalik M, Bobkowski W, Mroziński B, Surmacz R, Mrówczyński W, Wodziński A et al. Original articleShould perimembranous ventricular septal defects still be treated percutaneously?. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2008;4(1):1-9.

Aim: Assessment of perimembraneous ventricular septal defects (VSD) treatment with the use of AMembrVSDO and evaluation of the early and late complication risk. Methods: In the period from June, 2003 to August, 2005, 17 patients were qualified for VSD transcatheter closure. Patients aged 1.2-18.0 years (mean 9.2±6.5), weighted 9.4-72.0 kg (mean 32.9±21.8). The follow-up period was 3-4 years.
Results: The procedure was performed successfully in 15 out of 17 children. The left ventricle end-diastolic dimension decreased statistically after the procedure (p=0.00005). One child (6.7%) suffered from a complete atrioventricular block after the VSD closure. Minor complications were observed in 4 (26.7%) cases. Statistically significant differences were observed between the size of the device and the short diameter of the VSD (p=0.7600), the long diameter of the VSD (p=0.8152), the angiographic diameter of the VSD (p=0.9210) as well as the proposed device (p=0.9202). After VSD closure, the number of patients with TI >I° decreased from 66.7% to 6.7% (p=0.0159) and, in case of those with MI, from 93.3% to 60% (p=0.0270).
Conclusion: Percutaneous closure of the perimembranous VSD with AMembrVSDO is a promising method of treatment. Nevertheless, more frequent occurrence of the complete heart block following the above-mentioned procedure in comparison to surgery indicates that the qualification for AMembrVSDO implantation should be performed very carefully. More data is needed to verify safety of this procedure.

keywords:

Original articleShould perimembranous ventricular septal defects still be treated percutaneously?

Małgorzata Pawelec-Wojtalik , Waldemar Bobkowski , Bartłomiej Mroziński , Rafał Surmacz , Wojciech Mrówczyński , Andrzej Wodziński , Alicja Bartkowska-Śniatkowska , Rafał Bartkowski , Arkadiusz Biniaś

perimembranous ventricular septal defect, Amplatzer, transcatheter occlusion

Original article
Should perimembranous ventricular septal defects still be treated percutaneously?

Małgorzata Pawelec-Wojtalik

,

Waldemar Bobkowski

,

Bartłomiej Mroziński

,

Rafał Surmacz

,

Wojciech Mrówczyński

,

Andrzej Wodziński

,

Alicja Bartkowska-Śniatkowska

,

Rafał Bartkowski

,

Arkadiusz Biniaś